Abstract
Tuberculosis (TB) is the second cause of death from a single infectious agent, the M. tuberculosis bacillus. Nearly two billion people are infected and about 8.7 million new cases and 1.4 million deaths were reported by the World Health Organization (WHO) in 2013. Despite the availability of effective treatment, the alarming emergence of multidrug resistant (MDR) strains (with 310.000 estimated cases in 2011 among notified patients with pulmonary TB), simultaneously resistant to the two most effective anti-TB drugs, isoniazid (INH) and rifampicin, has urged the need to develop new molecular scaffolds, either structurally original or based on old and active drugs. The aim of this review is to summarize the current status of different QSAR based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent known, INH. A case study puts in evidence that the judicious application of quantitative structure- activity relationships can be successfully used to rationally design new INH-based derivatives, active against INH-resistant strains harboring mutations in the most frequent resistance related target (katG), and therefore develop candidate-compounds against MDR-TB, thus revisiting the unique effectiveness of INH against TB.
Keywords: Multidrug-resistance, tuberculosis, isoniazid, QSAR based-design, new antitubercular drugs.
Current Pharmaceutical Design
Title:QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB
Volume: 20 Issue: 27
Author(s): Filomena Martins, Cristina Ventura, Susana Santos and Miguel Viveiros
Affiliation:
Keywords: Multidrug-resistance, tuberculosis, isoniazid, QSAR based-design, new antitubercular drugs.
Abstract: Tuberculosis (TB) is the second cause of death from a single infectious agent, the M. tuberculosis bacillus. Nearly two billion people are infected and about 8.7 million new cases and 1.4 million deaths were reported by the World Health Organization (WHO) in 2013. Despite the availability of effective treatment, the alarming emergence of multidrug resistant (MDR) strains (with 310.000 estimated cases in 2011 among notified patients with pulmonary TB), simultaneously resistant to the two most effective anti-TB drugs, isoniazid (INH) and rifampicin, has urged the need to develop new molecular scaffolds, either structurally original or based on old and active drugs. The aim of this review is to summarize the current status of different QSAR based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent known, INH. A case study puts in evidence that the judicious application of quantitative structure- activity relationships can be successfully used to rationally design new INH-based derivatives, active against INH-resistant strains harboring mutations in the most frequent resistance related target (katG), and therefore develop candidate-compounds against MDR-TB, thus revisiting the unique effectiveness of INH against TB.
Export Options
About this article
Cite this article as:
Martins Filomena, Ventura Cristina, Santos Susana and Viveiros Miguel, QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118164434
DOI https://dx.doi.org/10.2174/1381612819666131118164434 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure-Activity Relationships of 2-Benzylsulfanylbenzothiazoles: Synthesis and Selective Antimycobacterial Properties
Medicinal Chemistry Identification of Proteins Interacting with Human SP110 During the Process of Viral Infections
Medicinal Chemistry Quickness of HIV and Tuberculosis Diagnostic Procedures in Prison of Tehran, Iran
Infectious Disorders - Drug Targets Web-Based Tools for the Interpretation of Chain-Like Protein Spot Patterns on Two-Dimensional Gels
Current Proteomics Enhancement of Immunoprotective Effect of CpG-ODN by Formulation with Polyphosphazenes Against E. coli Septicemia in Neonatal Chickens
Current Drug Delivery Using a Heat Diffusion Model to Detect Potential Drug Resistance Genes of <i>Mycobacterium tuberculosis</i>
Protein & Peptide Letters Novel Azole-Functionalited Flouroquinolone Hybrids: Design, Conventional and Microwave Irradiated Synthesis, Evaluation as Antibacterial and Antioxidant Agents
Letters in Drug Design & Discovery Anti-Inflammatory Properties of Drugs from saffron crocus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Perspectives and Prospects on mRNA Vaccine Development for COVID-19
Current Medicinal Chemistry Synthesis, Antibacterial and Antioxidant Activities of Some New Nsubstituted Azachalcone, Schiff base and Pyrazole Derivatives
Letters in Organic Chemistry Synthesis, Anticonvulsant and Antimicrobial Activities of Some New [1-(2-Naphthyl)-2-(pyrazol-1-yl)ethanone]oxime Ethers
Medicinal Chemistry LC-MS/MS Assay for Quantification of a Novel Antitubercular Molecule S006-830: Pharmacokinetic and Plasma Protein Binding Studies in Rats
Current Pharmaceutical Analysis Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Bioisosters of β-Lactams as Anti-Infectives
Current Medicinal Chemistry - Anti-Infective Agents Tumor Necrosis Factor Inhibitors in Pediatric Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Management of Pleural Effusions in the Emergency Department
Reviews on Recent Clinical Trials Synthesis and Anti-mycobacterium Study on Halo-substituted 2-aryl oxyacetohydrazones
Current Computer-Aided Drug Design Other Activities
Current Bioactive Compounds Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Constructive Personalized Medicine: The Potential Integration of Synthetic Biology and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine